Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Written informed consent~* Able to comply with the protocol~* ECOG performance status 0-1~* Adequate contraception~* Confirmed Her2/neu-positive, adenocarcinoma of the breast~* At least one measurable lesion according to RECIST 1.1 criteria~* First or second chemotherapy after diagnosis of metastasis~* Lapatinib treatment indicated (adjuvant trastuzumab treatment \<12 months ago or progressive disease with trastuzumab treatment)~* No signs and symptoms of CHF (chronic heart failure), LVEF (left ventricular ejection fraction) at study start at least 55%~* Adequate hepatic and renal function value~* Adequate hematologic function values~Exclusion Criteria:~* Pregnant or lactating women~* Concurrent participation in another clinical trial. Prior participation is allowed if the last study medication was administered more than 4 weeks prior to randomization~* Asymptomatic with regards to tumor illness~* Previous treatment with lapatinib, capecitabine or vinorelbine~* Necessity of planned treatment with other chemotherapeutics oder anti-hormone therapy~* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of the study~* Evidence of cardiovascular disease, e.g. myocardial infection, unstable angina pectoris or arrhythmia~* History of vascular or cardiovascular disease within the past 6 months~* All illnesses that result in malabsorption of oral medication or inability to take oral medication~* Concurrent treatment with anti-viral drugs based on sorivudine or with aminoglycosides~* Concurrent treatment with any drug interfering with study medication, especially, those that induce CYP3A~* Concurrent treatment with allopurinol~* Other malignancies (except for basal cell carcinoma of the skin and cervical carcinoma in situ); patient can be included in the study if no recurrent disease has been observed for at least 5 years~* Concurrent illnesses or other circumstances that could interfere with trial participation, efficacy or safety of the patient

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Capecitabine, Lapatinib, Vinorelbine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).